Melvin Olson

Melvin Olson

Company: Novartis

Job title: Global Head, RWD Strategy & Innovation


Skip Olson is currently the Global Head of RWD Strategy and Innovation at Novartis. As such, he is responsible for promoting the very best in research methodology and applications of Real World Data across all therapeutic areas and around the globe to drive better decision making. He comes from a background in HE&OR where he has led the use of RWE to transform the generation of patient insights and value for money assessments. He earned a PhD in Biostatistics from Harvard University and has worked in the pharmaceutical industry for over 25 years as a clinical statistician, HE&OR director, and RWE expert.


‘IMPACCT’ Panel Discussion: Advancing the Generation & Utilization of Real World Evidence to Drive Patient-Centricity & Better Outcomes 8:30 am

• Focusing on patient-centered drug development – what is the role of RWE? • Defining and establishing clinically meaningful evidence to support R&D • How to bring RWE-enhanced drug development one step forward? • Where does the biggest opportunity for next steps in this space lie? • Discussing the current regulatory climate in RWE •…Read more

day: Day One

Chair’s Closing Remarks 4:45 pm

Read more

day: Day Two

‘IMPACCT’ Panel Discussion: Looking Outwards – Demonstrating Product Value & Improved Care Delivery with Real World Evidence 4:00 pm

• Developing a suitable evidence framework to demonstrate product value and differentiation • Addressing external stakeholders’ (payors, providers and patients) concerns as they increasingly seek to understand the effects of new products in the real-world setting • Supporting decision-makers and payors with evidence that is better tailored to help them determine reimbursement policies and insurance…Read more

day: Day Two

Can Pharma Save $1 Billion Through the Strategic Use of RWE? 9:15 am

• Reviewing current evidence needs and trends • Introducing a framework for integrated evidence generation • Revisiting IMSHealth (now IQVIA) claims that Pharma can save $1 billion through real-world evidenceRead more

day: Day Two

‘IMPACCT’ Panel Discussion: Value Generation, Real World Evidence & Life Cycle Management – Distilling Strategy for Innovation 8:30 am

• In what stages of the drug life cycle does RWE have greatest impact? • Establishing the right evidence generation plan that meets clinical, regulatory and commercial needs of a product: • How to? • Does it differ between big and small pharma? • What’s the ROI vs. value generation? • Driving internal collaboration for…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.